ArticleClinical drug investigation2025

Cost-Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small-Cell Lung Cancer in Italy.

Andrea Marcellusi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.